NAFDAC approves Chloroquine as clinical drug for coronavirus

The National Agency for Food and Drug Administration and Control (NAFDAC) has approved Chloroquine as a clinical trial drug in the treatment of coronavirus.

This was disclosed by Mojisola Adeyeye, the Director-General of the agency while speaking at the NAFDAC headquarters in Lagos.

“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.

She also advised medical experts interested in using Chloroquine as a clinical trial to approach approved outlets.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of clinical trial,” Adeyeye added.